<?xml version="1.0" encoding="UTF-8"?>
<p id="Par137">AhR activation during IV infection disrupts host immunity and causes increased lung inflammation and mortality in mice [
 <xref ref-type="bibr" rid="CR42">42</xref>, 
 <xref ref-type="bibr" rid="CR64">64</xref>, 
 <xref ref-type="bibr" rid="CR165">165</xref>, 
 <xref ref-type="bibr" rid="CR172">172</xref>]. The suppression of AhR activity is assumed to attenuate IV-induced lung damage. The level of IV-induced IFNÎ² is increased in AhR-deficient cells and mice, thus leading to the suppression of viral replication [
 <xref ref-type="bibr" rid="CR64">64</xref>]. Several AhR antagonists, such as CH-223191 and Stem Regenin 1, have been identified; however, their therapeutic value against IV-infection-induced LI is unclear. Because AhR responds differentially to diverse intrinsic and extrinsic ligands and affects multiple types of immune cells [
 <xref ref-type="bibr" rid="CR172">172</xref>], a careful examination of the advantages and disadvantages of these AhR antagonists is required to assess their value in the treatment of IV infection.
</p>
